Watson Laboratories sued in ANDA filing fitted generic Opana ER
Watson Pharmaceuticals, Inc. (NYSE: WPI), a prime specialty pharmaceutical public limited company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued on Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in joint with the filing of Watson’s Brief Reborn Medicine Bearing (ANDA) respecting Oxymorphone Hydrochloride Extended-Release Tablets, 40mg. Watson’s Oxymorphone Hydrochloride Extended-Release Tablets effect is a generic rendition of Endo’s Opana® ER which is indicated repayment for the aid of modest to serious suffering in patients requiring uninterrupted, around-the-clock opioid treatment in the course of an extended duration of set. Opana® ER had nearly $245 million in trade-mark sales in spite of the twelve months ending December 31, 2009, according to IMS Well-being.
On January 19, 2010, pursuant to the Hatch-Waxman Front, Watson notified Endo and Penwest that its ANDA contained a paragraph IV certification asserting that U.S. Clear Nos. 5,662,933, 5,958,456, and 7,276,250, which are listed in the Orange Words on account of Opana® ER, are ill, unenforceable and/or not infringed.
OUTSET Watson Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
